TARO(Delisted)
Taro Pharmaceutical Industries·NYSE
--
--(--)
TARO fundamentals
Taro Pharmaceutical Industries (TARO) released its earnings on May 18, 2018: revenue was -- (YoY 0.00%), beat estimates; EPS was -- (YoY 0.00%), met estimates.
Revenue / YoY
--
0.00%
EPS / YoY
--
0.00%
Report date
May 18, 2018
EPS
Revenue
Revenue & Expenses
TARO has released its 2024 Q4 earnings report, with revenue of 164.94M, reflecting a YoY change of 12.52%, and net profit of 15.08M, showing a YoY change of 118.11%. The Sankey diagram below clearly presents TARO's revenue sources and cost distribution.
Key Indicators
Taro Pharmaceutical Industries (TARO) key financial stats and ratios, covering profitability, financial health, and leverage.
Taro Pharmaceutical Industries (TARO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Taro Pharmaceutical Industries (TARO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Taro Pharmaceutical Industries (TARO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Taro Pharmaceutical Industries (TARO) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Taro Pharmaceutical Industries (TARO) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
No Data
